LRRC43 Inhibitors
Chemical inhibitors of LRRC43 function through various mechanisms to disrupt the normal biosynthetic and degradative pathways of the protein. Cycloheximide acts by shutting down protein synthesis at the translation level, directly preventing the production of LRRC43. Chloroquine and brefeldin A target different aspects of the intracellular trafficking and degradation pathways; Chloroquine impairs lysosomal function, which is crucial for the breakdown of proteins, leading to an accumulation of LRRC43 if it is defective or damaged. Brefeldin A disrupts the Golgi apparatus, where proteins like LRRC43 are modified and sorted, which can lead to improper protein folding and processing. Tunicamycin, on the other hand, inhibits N-linked glycosylation, a post-translational modification that is essential for the stability and function of many proteins, potentially affecting the structure and function of LRRC43 if it undergoes glycosylation.
Inhibitors such as MG-132, E-64, and lactacystin exert their effects by disrupting the proteasome pathway, which is responsible for degrading ubiquitinated proteins. This inhibition can result in the buildup of proteins, possibly including misfolded or dysfunctional LRRC43. Similarly, leupeptin and ALLN (Calpain Inhibitor I) prevent the action of lysosomal proteases and calpains respectively, which could lead to the accumulation and reduced turnover of LRRC43. Pepstatin A targets aspartic proteases, which might affect LRRC43 by interfering with its proteolytic processing. Puromycin and α-amanitin disrupt protein synthesis by causing premature termination during translation and inhibiting RNA polymerase II, respectively. These disruptions can lead to the production of incomplete proteins or the suppression of new protein synthesis, including that of LRRC43, resulting in its functional inhibition. Each of these chemicals, by targeting specific cellular pathways and processes, can contribute to the inhibition of the proper function of LRRC43 within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
This chemical inhibits protein synthesis by interfering with the translocation step in protein elongation on the ribosome, which can lead to a reduction in LRRC43 function due to decreased synthesis of the protein. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine disrupts lysosomal function and autophagy, processes that are essential for the degradation of proteins. By inhibiting these pathways, Chloroquine can lead to an accumulation of misfolded or damaged proteins, including LRRC43, thus inhibiting its function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus structure and function, which can lead to a blockade in the secretory pathway. This disruption can prevent proper folding and processing of LRRC43, thereby inhibiting its function. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation in the ER. Since glycosylation is critical for the proper folding and stability of many proteins, this chemical can lead to functional inhibition of LRRC43 if it requires glycosylation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins. This inhibition can lead to the accumulation of proteins that may include misfolded or nonfunctional LRRC43, thus inhibiting its function. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 irreversibly inhibits cysteine proteases, which can lead to an accumulation of proteins within the cell. This can inhibit LRRC43 function by disturbing its degradation or turnover if it is subject to cysteine protease action. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin inhibits lysosomal thiol proteases, such as cathepsins, which are involved in protein turnover. Inhibition of these enzymes can lead to an accumulation of proteins including LRRC43, potentially inhibiting its function. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome, which can inhibit the degradation of ubiquitin-tagged proteins, leading to an accumulation of defective or misfolded proteins including LRRC43, inhibiting its function. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $166.00 $322.00 | 436 | |
Puromycin causes premature chain termination during protein synthesis. This can lead to the production of truncated, nonfunctional proteins, which can include LRRC43, thereby inhibiting its function. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin inhibits RNA polymerase II, which is essential for mRNA synthesis. This can result in the suppression of the synthesis of new proteins, including LRRC43, leading to a functional inhibition of the protein. | ||||||